Current Value
$0.651 Year Return
Current Value
$0.651 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -26.68% | $109.64M | 0.85% |
BTAL | -22.49% | $361.41M | 1.43% |
TAIL | -19.19% | $140.49M | 0.59% |
USDU | -13.53% | $173.44M | 0.5% |
FTSD | -9.26% | $212.46M | 0.25% |
CLIP | -8.83% | $1.50B | 0.07% |
IVOL | -8.46% | $353.94M | 1.02% |
UUP | -7.96% | $292.27M | 0.77% |
TPMN | -6.83% | $31.54M | 0.65% |
SHYM | -6.72% | $322.93M | 0.35% |
ULST | -6.54% | $637.77M | 0.2% |
KMLM | -5.77% | $188.32M | 0.9% |
NEAR | -5.35% | $3.26B | 0.25% |
AGZD | -4.96% | $127.42M | 0.23% |
WEAT | -3.76% | $115.83M | 0.28% |
SCHO | -3.76% | $10.87B | 0.03% |
GSST | -3.40% | $857.21M | 0.16% |
GBIL | -3.03% | $6.17B | 0.12% |
SHYD | -2.94% | $318.05M | 0.35% |
BILZ | -2.93% | $876.85M | 0.14% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 43.36% | $40.65M | 0.5% |
XBI | 41.70% | $4.85B | 0.35% |
IBB | 40.22% | $5.22B | 0.45% |
ARKG | 38.88% | $944.78M | 0.75% |
BBH | 36.70% | $327.42M | 0.35% |
PBE | 36.41% | $214.12M | 0.58% |
PTH | 35.81% | $96.56M | 0.6% |
PINK | 35.80% | $131.52M | 0.5% |
CPRJ | 35.77% | $48.43M | 0.69% |
IWMY | 35.63% | $109.62M | 1.02% |
FBT | 35.41% | $994.71M | 0.56% |
KJUL | 33.88% | $113.35M | 0.79% |
IWC | 33.25% | $766.88M | 0.6% |
IWO | 30.62% | $11.36B | 0.24% |
IWM | 30.26% | $63.95B | 0.19% |
VTWO | 30.23% | $12.07B | 0.07% |
VHT | 30.15% | $14.92B | 0.09% |
KJAN | 29.62% | $305.13M | 0.79% |
XDTE | 29.46% | $382.21M | 0.95% |
RIET | 29.34% | $87.22M | 0.5% |
Finnhub
Two programs with clinical data readouts in 2H/2025Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment...
Finnhub
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement...
Finnhub
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor,...
Yahoo
REDWOOD CITY, Calif. & BOSTON, April 17, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies.
Yahoo
REDWOOD CITY, Calif. & BOSTON, March 31, 2025--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 7, 2025.
Yahoo
We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are going to take a look at where Adicet Bio, Inc. (NASDAQ:ACET) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 and attract investors looking for high returns with […]
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RGNX | 41.36% | $433.39M | -46.03% | 0.00% |
ALEC | 38.32% | $110.49M | -79.87% | 0.00% |
ARWR | 37.50% | $2.12B | -38.64% | 0.00% |
PHAT | 37.44% | $242.95M | -67.45% | 0.00% |
FATE | 36.49% | $115.78M | -75.60% | 0.00% |
DVAX | 36.19% | $1.14B | -15.69% | 0.00% |
RXRX | 36.11% | $1.73B | -55.31% | 0.00% |
BEAM | 35.53% | $1.73B | -27.49% | 0.00% |
YMAB | 35.03% | $174.80M | -67.43% | 0.00% |
CRSP | 35.01% | $3.14B | -34.78% | 0.00% |
BLFS | 34.94% | $1.05B | +0.09% | 0.00% |
PDSB | 34.73% | $61.66M | -61.76% | 0.00% |
NTLA | 34.41% | $836.43M | -69.14% | 0.00% |
SYRE | 34.37% | $877.54M | -61.53% | 0.00% |
NXTC | 34.30% | $11.56M | -75.03% | 0.00% |
DIOD | 33.97% | $2.25B | -33.06% | 0.00% |
GOGO | 33.73% | $1.61B | +13.70% | 0.00% |
NRIX | 33.24% | $721.19M | -38.57% | 0.00% |
SDGR | 33.11% | $1.71B | +2.01% | 0.00% |
CLFD | 32.79% | $538.99M | +5.27% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SUP | -12.57% | $16.71M | -84.80% | 0.00% |
TPB | -11.26% | $1.29B | +113.31% | 0.40% |
CDRE | -10.40% | $1.43B | +17.79% | 1.04% |
PULM | -9.11% | $23.82M | +239.64% | 0.00% |
MO | -9.04% | $97.80B | +26.35% | 6.94% |
DCGO | -8.85% | $138.75M | -56.25% | 0.00% |
CLX | -8.72% | $16.64B | -1.45% | 3.61% |
CME | -7.73% | $98.74B | +28.80% | 3.84% |
CMG | -7.19% | $70.12B | -17.29% | 0.00% |
MBI | -6.72% | $245.31M | -17.88% | 0.00% |
CBOE | -6.47% | $22.95B | +20.67% | 1.12% |
CVRX | -6.27% | $161.39M | -23.39% | 0.00% |
ELAN | -5.14% | $6.43B | -23.79% | 0.00% |
CABO | -5.09% | $926.89M | -58.34% | 7.13% |
K | -5.06% | $28.49B | +32.17% | 2.77% |
DV | -5.00% | $2.34B | -23.73% | 0.00% |
CYCN | -4.34% | $9.37M | +2.39% | 0.00% |
KO | -4.31% | $308.23B | +13.09% | 2.75% |
NOC | -4.22% | $67.51B | -0.35% | 1.76% |
LQDT | -4.13% | $769.90M | +25.50% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
USO | 0.05% | $956.18M | 0.6% |
DBO | 0.06% | $182.54M | 0.77% |
CGMU | -0.13% | $3.10B | 0.27% |
USL | -0.14% | $41.76M | 0.85% |
TBIL | 0.15% | $5.76B | 0.15% |
LGOV | -0.17% | $684.47M | 0.67% |
IBD | 0.19% | $380.12M | 0.43% |
TDTT | -0.23% | $2.47B | 0.18% |
BNO | 0.28% | $86.13M | 1% |
OILK | 0.31% | $63.21M | 0.69% |
BILS | 0.39% | $3.96B | 0.1356% |
STPZ | 0.40% | $446.46M | 0.2% |
CCOR | 0.42% | $59.79M | 1.18% |
UGA | 0.45% | $73.47M | 0.97% |
XONE | -0.47% | $603.24M | 0.03% |
SGOV | 0.55% | $45.91B | 0.09% |
IBTG | -0.58% | $1.88B | 0.07% |
CTA | 0.68% | $1.05B | 0.76% |
USTB | 0.77% | $1.19B | 0.35% |
MUST | 0.80% | $403.58M | 0.23% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
ARLP | -0.04% | $3.42B | +17.02% | 10.52% |
COR | 0.04% | $55.43B | +28.90% | 0.56% |
HUSA | -0.08% | $9.73M | -55.71% | 0.00% |
PARR | 0.10% | $1.06B | -28.69% | 0.00% |
TR | 0.12% | $2.37B | +11.85% | 1.10% |
ASPS | -0.12% | $69.98M | -57.72% | 0.00% |
VSA | 0.15% | $7.04M | -49.24% | 0.00% |
VSTA | 0.19% | $326.82M | +11.64% | 0.00% |
ANF | -0.23% | $3.79B | -41.29% | 0.00% |
LMT | -0.23% | $108.98B | +0.07% | 2.79% |
WCN | 0.25% | $49.35B | +14.58% | 0.65% |
AEP | 0.27% | $54.28B | +9.80% | 3.61% |
FATBB | -0.29% | $50.77M | -11.65% | 9.83% |
FE | 0.29% | $24.49B | +5.52% | 4.06% |
EGO | 0.29% | $3.68B | +17.14% | 0.00% |
DXCM | -0.31% | $33.59B | -35.05% | 0.00% |
HNRG | -0.36% | $811.82M | +223.46% | 0.00% |
MQ | 0.37% | $2.34B | -11.50% | 0.00% |
DG | 0.38% | $20.45B | -36.56% | 2.55% |
PRGS | -0.41% | $2.69B | +21.12% | 0.56% |